L-AmB_ Retrospective mUlticenter Study on Mycosis prOphylaxis
Launched by ISTITUTO GIANNINA GASLINI · Oct 10, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Invasive fungal disease (IFD) still represents an important cause of morbidity and mortality in immunocompromised patients, particularly in patients undergoing antineoplastic chemotherapy or allogeneic hemopoietic stem cell transplantation (allo-HSCT). In this setting children presents some differences compared to adults in terms of risk factors for IFD: different treatment schemes, age-related comorbidities, diagnostic tools with different sensitivity. International guidelines strongly recommend primary prophylaxis in children at high risk of developing IFD to reduce disease-related morbid...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients at high risk of developing IFD receiving chemotherapy for (1st line or relapse treatment) or allo-HSCT for which primary fungal prophylaxis with extended dosing of liposomal amphotericin B has been administered
- Exclusion Criteria:
- • previous diagnosis of IFD (secondary prophylaxis),
- • contraindications to liposomal amphotericin B prophylaxis
About Istituto Giannina Gaslini
Istituto Giannina Gaslini is a renowned pediatric research institute located in Genoa, Italy, dedicated to advancing child health through innovative clinical research and high-quality care. As a leading center in pediatric medicine, the institute focuses on a wide range of specialties, including oncology, immunology, and rare diseases. Committed to improving patient outcomes, Istituto Giannina Gaslini actively engages in clinical trials that explore new therapeutic strategies and enhance existing treatments. With a multidisciplinary team of experts, the institute fosters collaboration with national and international partners to contribute to the global body of pediatric medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Genoa, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported